Efficacy and Safety of JAK Inhibitors in Systemic Sclerosis-associated Interstitial Lung Disease
Condition(s):Systemic Sclerosis; Interstitial Lung DiseaseLast Updated:August 3, 2023Recruiting
Include Studies Not Open or Pending
Condition(s):Systemic Sclerosis; Interstitial Lung DiseaseLast Updated:August 3, 2023Recruiting
Condition(s):Rheumatoid ArthritisLast Updated:February 7, 2024Recruiting
Condition(s):Colitis, UlcerativeLast Updated:December 22, 2022Recruiting
Condition(s):Rheumatoid Arthritis; Inflammatory Rheumatism; Psoriatic Arthritis; SpondyloarthritisLast Updated:March 25, 2024Recruiting
Condition(s):Abatacept; Treatment Compliance; Rheumatoid ArthritisLast Updated:September 23, 2022Recruiting
Condition(s):Arthritis, Rheumatoid; Arthritis, Psoriatic; SpondyloarthritisLast Updated:March 29, 2021Recruiting
Condition(s):Hemophagocytic SyndromesLast Updated:February 6, 2024Not yet recruiting
Condition(s):Primary Myelofibrosis; Secondary MyelofibrosisLast Updated:January 5, 2024Recruiting
Condition(s):Toxic Epidermal NecrolysisLast Updated:November 28, 2023Recruiting
Condition(s):Rheumatoid ArthritisLast Updated:October 12, 2022Not yet recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.